How 'hidden mutations' contribute to HIV drug resistance

One of the major reasons that treatment for HIV/AIDS often doesn't work as well as it should is resistance to the drugs involved. Now, scientists at McGill University have revealed how mutations hidden in previously ignored parts of the HIV genome play an important role in the development of drug resistance in AIDS patients. Their study will be published Aug. 8 in the Journal of Biological Chemistry.

"HIV develops resistance very rapidly, and once that happens, drugs don't work as well as they theoretically should, or they stop working altogether," explained Dr. Matthias Götte, an associate professor in McGill's Department of Microbiology and Immunology. "Physicians routinely have the patient's virus tested for resistance in advance of treatment to help make the appropriate clinical decisions."

The study was conducted by a team of researchers led by Dr. Götte at McGill's Faculty of Medicine, with assistance from the B.C. Centre for Excellence in HIV/AIDS at the University of British Columbia (UBC). It was funded by the Canadian Institutes for Health Research (CIHR).

HIV genotype testing is now widely established in HIV drug resistance screening. However, for technical and economic reasons, the entire HIV genome is usually not sequenced.

"The focus has been on specific areas of the HIV genome where we expect these resistance-conferring mutations to occur," Dr. Götte said. "We focus on a particular sequence on an important gene from amino acid 1 to 300, and as such, we miss roughly a third of this gene. Until recently, most researchers believed that this hidden area was of little clinical significance."

Within the last few years, however, studies started to suggest that the first 300 amino acids alone may not completely describe the drug resistance landscape. Dr. Götte and his colleagues selected a few of these previously uncharacterized mutations and subjected them to a battery of highly sensitive biochemical tests.

"People were skeptical," Dr. Götte said. "The mechanism about how these mutations could be involved in resistance was not clear. However, in our paper, we present data that explains in considerable detail how these mutations work."

Nevertheless, he cautioned, the debate about whether to routinely screen these areas of the HIV genome will still likely continue for some time.

"It's extremely time-consuming and expensive to validate genotype testing," he said. "However, we probably will be testing these areas in a couple of years."

Source: McGill University

Related stories:

New class of antibiotics may lead to therapy for drug-resistant tuberculosis
A team of Rutgers University scientists led by Richard H. Ebright and Eddy Arnold has identified a new antibiotic target and a new antibiotic mechanism that may enable the development of broad-spectrum antibacterial agents effective against bacterial pathogens resistant to current antibiotics. In particular, the results could lead the way to new treatments for tuberculosis (TB) that involve shorter courses of therapy and are effective against drug-resistant TB.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, has been shown to be effective over 48 weeks for drug-resistant patients with R5 HIV-1, a variation of the virus found in more than half of HIV-infected patients.
New study finds HIV drug can persist in mothers' milk, increasing risk to them and their babies
A drug commonly used in the developing world to prevent transmission of HIV from mother to child persists in the breast milk and blood of the mothers, putting them and their babies at risk for developing drug-resistant strains of the virus, according to researchers at the Stanford University School of Medicine.
Sensitive testing reveals drug-resistant HIV with possible consequences for treatment
Drug-resistant HIV at levels too low to be detected by standard tests is not unusual and may contribute to treatment failure, according to research published in PLoS Medicine.
Zinc finger proteins put personalized HIV therapy within reach
Researchers at the University of Pennsylvania School of Medicine and collaborators are using minute, naturally occurring proteins called zinc fingers to engineer T cells to one day treat AIDS in humans.
Research findings open new front in fight against AIDS virus
A research group supported by the National Institutes of Health (NIH) has uncovered a new route for attacking the human immunodeficiency virus (HIV) that may offer a way to circumvent problems with drug resistance. In findings published today in the online edition of the Proceedings of the National Academy of Sciences, the researchers report that they have blocked HIV infection in the test tube by inactivating a human protein expressed in key immune cells.
Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
A mathematical model shows that a new wave of drug-resistant HIV is rising among among men in San Francisco who have sex with men and that this trend will continue over the next few years, according to a new study from the UCLA AIDS Institute.
Virtual human in HIV drug simulation
The combined supercomputing power of the UK and US ‘national grids’ has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus. The method – an early example of the Virtual Physiological Human in action – could one day be used to tailor personal drug treatments, for example for HIV patients developing resistance to their drugs.

News discussion:

Medicine & Health news